It would not surprise me. They will have to raise money at some point. It won't be a bad thing. They could sell 10 million shares and raise $100 million. The offering would probably be over-subscribed, therefore not hurting the pps significantly. Just my opinion. (I'm assuming an offering price of at least $10.50 per share.)
given the amount of money they have and the burn ratie, I would think they would wait until after filing NDA. They would get a nice pop for filing and therefore either less dilution or more money raised. Either way, that would be a win for the shareholders.
Look at how the secondary offering rumor got started: Scott Matusow. The guy is a trader. Guess when he started the rumor? After he sold his shares. There is no reason to believe that the company will raise cash right now. They have a helluvalot of it, and a partnership or buyout is heavily looming. If neither of those things occur this year, you'll probably see a cash raise, but I doubt that would come until next year.
Its in the back of my mind too and is a good guage to on whether any deals happen sooner rather than later? I think any dilution will tell us more about the status of any partnership or buyout than it actually hurts doing the dilution in this space before regulatory!
Myself I don;t think any deal here comes until after US approval of "Ted", but others think different and I am trying to keep an open mind here.
We will see---wouldn;t rule dilution in or out---just a possibility depending on the situation internally. This is still a good company and stock with a drug that has hooks to sell in their space---can't argue that unless one is dumb!